San Diego, California (September 10, 2019)/PRNewswire/ – Biosortia, a leader in the next frontier of drug discovery, accessing the enormous chemical and genomic potential of natural microbiomes, is pleased to announce the addition of leading metabolomics expert, Dr. John Ryals to the Board of Directors.

“It is an honor to have Dr. Ryals join the Board of Directors of Biosortia Pharmaceuticals,” said Ross Youngs, Biosortia’s Founder, Chairman, and CEO. “John has a proven track record of building professional and scientifically successful biotech companies. John is also a trailblazer who has advanced the understanding of human health with vision, strategy, and operational excellence. Biosortia’s business of drug discovery using unique capabilities to obtain the hidden drug-like chemistry of microbiome is complemented by Dr. Ryals.”

“I am very excited and honored to be named as a Director to Biosortia’s Board,” said Dr. Ryals. “Biosortia’s distinct capability to access and demonstrate the extraordinary potential of aquatic microbiomes, small molecules/metabolites and their pathways as the foundation of life sciences research, can be a game-changer in terms of therapeutic discovery. The synergy of Biosortia’s ability to access this next frontier of metabolomic chemistry with my background in biomedical engineering can have a far-reaching effect on developing immuno-therapeutics.”

Founder of Metabolon and serving as CEO and Board member for 16 years, Dr. Ryals has 30 years of experience in the biotechnology industry, including senior research positions at Novartis and Ciba-Geigy. He is now the Chairman Emeritus, Founder, and Board Member at Metabolon. Prior to founding Metabolon, Dr. Ryals was chief executive officer, president, and founder of Paradigm Genetics, Inc., a publicly-traded agricultural biotechnology company focused on industrializing the process of gene function discovery. He currently serves on the board of directors at AgBiome, a provider of early-stage R&D for agriculture, and the advisory board of the College of Agriculture and Life Sciences at North Carolina State University. He earned a B.A. in biology and chemistry from the University of North Texas and an M.S. and Ph.D. degrees in molecular biology from the University of Texas at Dallas.

###

About Biosortia Pharmaceuticals – Biosortia has a proven and unique ability to obtain unculturable aquatic microbial consortia from the natural environment in unprecedented quantities allowing its research team to discover a diverse array of new natural products. Biosortia is actively engaging pharmaceutical research and development organizations to explore the huge opportunity of exploring aquatic microbial consortia for potential therapeutic agents.

About JLABS – The Biosortia Pharmaceutical operations are located at JLABS in San Diego (JLABS @SD). JLABS is a 40,000 square-foot life science innovation center, located in San Diego. The labs provide a flexible environment for start-up companies pursuing new technologies and research platforms to advance medical care. Through a “no strings attached” model, JJI does not take an equity stake in the companies occupying JLABS and the companies are free to develop products – either on their own or by initiating a separate external partnership with JJI or any other company.

If you’d like more information about the announcement or Biosortia, please contact Chad Hummell of Biosortia at 614-203- 8040 or ch******@*******ia.com.